European medicines agencies network strategy
Submitted by Anonymous (not verified) on 9 October 2024 - 12:58
European medicines agencies network strategy
Towards the European medicines agencies network strategy 2028: Reflection paper
Submitted by Anonymous (not verified) on 9 October 2024 - 12:57
Towards the European medicines agencies network strategy 2028: Reflection paper
Seizing opportunities in a changing medicines landscape: The European medicines agencies network strategy 2028 (draft)
Submitted by Anonymous (not verified) on 9 October 2024 - 12:56
Seizing opportunities in a changing medicines landscape: The European medicines agencies network strategy 2028 (draft)
PSUSA/00002673/202312
Submitted by Anonymous (not verified) on 9 October 2024 - 11:50
PSUSA/00002673/202312
PSUSA/00010696/202401
Submitted by Anonymous (not verified) on 9 October 2024 - 11:48
PSUSA/00010696/202401
PSUSA/00010864/202401
Submitted by Anonymous (not verified) on 9 October 2024 - 11:48
PSUSA/00010864/202401
PSUSA/00000230/202402
Submitted by Anonymous (not verified) on 9 October 2024 - 11:46
PSUSA/00000230/202402
Applications for new human medicines under evaluation: October 2024
Submitted by Anonymous (not verified) on 8 October 2024 - 15:58
Applications for new human medicines under evaluation: October 2024
Human medicines European public assessment report (EPAR): Oxbryta, Voxelotor, Date of authorisation: 14/02/2022, Revision: 5, Status: Suspended
Submitted by Anonymous (not verified) on 8 October 2024 - 15:25
Human medicines European public assessment report (EPAR): Oxbryta, Voxelotor, Date of authorisation: 14/02/2022, Revision: 5, Status: Suspended
Antimicrobial Sales and Use (ASU) Platform: Release notes
Submitted by Anonymous (not verified) on 8 October 2024 - 15:20
Antimicrobial Sales and Use (ASU) Platform: Release notes